There are also studies reporting the impact of neoadjuvant therapy on PD-L1 expression and CD8+ lymphocyte density in NSCLC (75).Studies have demonstrated that EBV-specific CD8+ TILs in EBV-driven PLEC exhibit heterogeneity and partial deficiency in PD-1 expression (76). Here, CD8A is linked to non-small cell lung carcinoma.